Humira (adalimumab) / AbbVie, Eisai  >>  Phase 4
Welcome,         Profile    Billing    Logout  

211 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Humira (adalimumab) / AbbVie
NCT07352566: Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting
4
10
US
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
University of California, San Francisco
Psoriasis, Atopic Dermatitis
06/30
06/30
ADATOFTAK, NCT05151848: Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Recruiting
4
100
RoW
Adalimumab Injection, An-jian-ning, Tofacitinib 5 MG, An-shu-zheng
Chinese SLE Treatment And Research Group
Takayasu Arteritis
01/26
01/26
NCT05105347: Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Not yet recruiting
4
130
NA
Adalimumab plus different doses of oral glucocorticosteroid, Humira, prednisone
Peking Union Medical College Hospital
Uveitis
12/26
12/26
NCT05928039: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Recruiting
4
297
Canada
TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab, Anti-IL12/23 or anti-IL23 - Risankizumab, Anti-integrin - Vedolizumab IV, Anti-integrin - Vedolizumab IV and SC
University of Calgary, Alimentiv Inc.
Crohn Disease
07/27
12/28
SOPRANO-CD, NCT05169593: Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy

Recruiting
4
292
Europe
Biological Drug, Risankizumab, Vedolizumab, Ustekinumab, Infliximab, Adalimumab
Universitaire Ziekenhuizen KU Leuven
Crohn Disease
10/27
10/30
ChiCTR2500106175: A Multicenter, Single-arm Study to Evaluate the Efficacy and Safety of Anjianning® in Adult Patients with Moderately to Severely Active Crohn 's Disease in the Real-world

Not yet recruiting
4
60
 
Adalimumab Solution for Injection
The Second Affiliated Hospital of AFMU; Bioray Pharmaceutical (Hangzhou) Co., Ltd, raise independently
Crohn 's disease
 
 
ChiCTR2500104254: The effectiveness and safety of Anjianning(adalimumab) for the treatment of autoimmune diseases in the real-world: A multicenter, prospective, observational study

Not yet recruiting
4
10000
 
NA ; NA ; NA
ShangHai GuangHua Hospital of Integrated Traditiona.Chinese and Western Medicine; Bioray Pharmaceutical (Hangzhou) Co., Ltd, Bioray Pharmaceutical (Hangzhou) Co., Ltd
Autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis)
 
 
ChiCTR2500102833: Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu’s Arteritis

Not yet recruiting
4
50
 
6mg QD orally for 24 weeks; Adalimumab is administered as 40 mg by subcutaneous injection every 2 weeks, for 24 weeks
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-financing
Takayasu's arteritis
 
 
ChiCTR2500107834: A single-center, single-arm phase II clinical study of albumin-bound paclitaxel combined with carboplatin and adebrelimab for neoadjuvant treatment of thymic carcinoma

Not yet recruiting
4
40
 
Neoadjuvant: Adalimumab + Albumin Paclitaxel + Carboplatin, quaque 3 weeks, 2-3 cycles → Surgery → Adjuvant: Adalimumab + Albumin Paclitaxel + Carboplatin, quaque 3 weeks, 2-3 cycles → Adalimumab, quaque 3 weeks . Adalimumab up to 35 cycles.
Nanjing Drum Tower hospital; Nanjing Drum Tower hospital, NONE
thymic carcinoma
 
 
ORAL STRATEGY, NCT02187055 / 2014-000358-13: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Hourglass Jan 2017 - Mar 2017 : From ORAL STRATEGY trial in rheumatoid arthritis
Checkmark ORAL STRATEGY
Feb 2017 - Feb 2017: ORAL STRATEGY
Completed
3b/4
1152
US, Canada, Europe, RoW
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Pfizer
Rhematoid Arthritis
12/16
12/16
NCT02092467 / 2013-003177-99: Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Checkmark Safety data from post-marketing study in rheumatoid arthritis
Jul 2021 - Jul 2021: Safety data from post-marketing study in rheumatoid arthritis
Checkmark Efficacy and safety data from post-marketing required safety study in rheumatoid arthritis
Jan 2021 - Jan 2021: Efficacy and safety data from post-marketing required safety study in rheumatoid arthritis
Completed
3b/4
4372
Europe, Canada, US, RoW
tofacitinib, adalimumab, Humira, etanercept, Enbrel
Pfizer
Arthritis, Rheumatoid
07/20
07/20
 

Download Options